Compare RBB & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBB | MYGN |
|---|---|---|
| Founded | 2008 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 451.0M | 444.2M |
| IPO Year | 2017 | 1996 |
| Metric | RBB | MYGN |
|---|---|---|
| Price | $26.56 | $5.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $22.00 | $7.64 |
| AVG Volume (30 Days) | 203.3K | ★ 1.0M |
| Earning Date | 04-20-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.68% | N/A |
| EPS Growth | ★ 24.49 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | $5,167,000.00 | ★ $771,400,000.00 |
| Revenue This Year | $20.50 | $6.86 |
| Revenue Next Year | $6.90 | $5.45 |
| P/E Ratio | $39.82 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $16.74 | $3.53 |
| 52 Week High | $28.24 | $8.59 |
| Indicator | RBB | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.36 | 48.29 |
| Support Level | $20.11 | $4.24 |
| Resistance Level | $28.22 | $5.71 |
| Average True Range (ATR) | 0.80 | 0.28 |
| MACD | -0.20 | -0.11 |
| Stochastic Oscillator | 34.06 | 1.09 |
RBB Bancorp operates as a bank holding company. It provides various banking products and services such as checking, savings, money market accounts, and certificates of deposits. Its Specific services include remote deposit, E-banking, mobile banking, commercial and investor real estate loans, business loans and lines of credit, Small Business Administration (SBA) 7A and 504 loans, mortgage loans, trade finance, and a full range of depository accounts. It generates its revenue from interest received on loans and leases and, to a lesser extent, from interest received on investment securities and derives income from noninterest sources, such as fees received in connection with various lending and deposit services, loan servicing, gain on sales of loans, and wealth management services.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.